Acupuncture Study on Rheumatoid Arthritis, Monitoring Microbiome and Blood

Last updated: November 8, 2023
Sponsor: Chinese Academy of Sciences
Overall Status: Completed

Phase

N/A

Condition

Joint Injuries

Dermatomyositis (Connective Tissue Disease)

Rheumatoid Arthritis

Treatment

non-steroidal anti-inflammatory drug (NSAID)

Acupuncture

leflunomide

Clinical Study ID

NCT01619176
acumicro
  • Ages 18-65
  • Female
  • Accepts Healthy Volunteers

Study Summary

Acupuncture is used and recommended by the WHO for the treatment of Rheumatoid Arthritis.

The molecular bases of this recommendation are not known, the investigators want to compare with the usage of high-throughput molecular technologies the variations occurring in patients treated with acupuncture and conventional treatment with the ones treated with conventional treatment only. The investigators observe the variations in blood and in the gut microbiome.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • The patient should be diagnosed as the first or second stage of rheumatoid Arthritis (RA) and checked with X ray for additional diagnose.
  • diagnosed for RA according to ACR(1987)
  • the patient should be in the active stage of the disease, defined as:
  1. swollen joints >3
  2. tender joints > 5
  3. any one of the following: (c1.) morning stiffness lasting more than 45 minutes (c2.) Erythrocyte Sedimentation Rate (ESR) >= 28mm/h (c3.) C-reactive protein (CRP)>= 12mg/L
  • Should not be resistant to MTX nor leflunomide
  • Blood test should satisfy:
  1. Hemoglobin (Hb)>=85g/L
  2. White cell >=3.5 10+9/L
  3. Platelets >= 100 10+9/L
  4. Liver function: serum alanine aminotransaminase (ALT), aspartate transaminase (AST) and total bilirubin (TBil) should be less than 1.5 times the upper limit ofnormal (ULN)
  5. Kidney function: Serum creatinine (Cr) level should be less than ULN.
  6. Pregnancy test should be negative
  • should be positive for anti-cyclic citrullinated protein antibodies (anti-CCP).
  • should agree to sign the informed consent

Exclusion

Exclusion Criteria:

  • Serious diseases affecting liver, kidney, heart and lung, or diseases related tohematologic,endocrine and nervous systems. .
  • Be treated by MTX or Leflunomide in the last 3 months.
  • Be treated with cortical hormone (could be intramuscular injection, intravenousinjection or injection to articular cavity) in the last 4 weeks.
  • Be treated with biological agents, such as antagonist of TNF-alpha,IL-6, and CD20 monoantibody in the last 3 months.
  • Be treated by chronic medicine, such as immunosuppressive agent, Penicillamine,chloroquine and gold based Disease-modifying antirheumatic drugs (DMARDs) in the last 3 months.
  • Pregnant and breast-feeding woman
  • Having history of serious drug allergy
  • In the acute or chronic phase of infection (such as lung diseases)
  • Easy bleeding patients or patients with local skin infection (only for acupuncture)
  • The patients cannot accept acupuncture (only for acupuncture)
  • Be treated with acupuncture in the past 3 months(only for acupuncture).
  • No pregnant and breast-feeding woman.
  • No history of serious drug allergy.

Study Design

Total Participants: 10
Treatment Group(s): 4
Primary Treatment: non-steroidal anti-inflammatory drug (NSAID)
Phase:
Study Start date:
October 01, 2012
Estimated Completion Date:
December 31, 2014

Connect with a study center

  • Shanghai GuangHua Hospital of integrated traditional and western medicine

    Shanghai, Shanghai 200052
    China

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.